Áõ·Ê   Çлý¹ßÇ¥   °øÇØ   ¸é¿ªÄ¡·á   ÇÑÀÇÇп¡ ´ëÇÑ ³ªÀÇ ÀÌÇØ 
 
[¸ÞÀϸµ½Åû/Å»Åð]
  °íÁ¤°Ë»ö :  ¾Ë·¹¸£±â°³·Ð  /  ¾Ë·¹¸£°Õ  /  ±â°üÁöõ½Ä  /  ¾ÆÅäÇÇÇǺο°  /  À½½Ä¾Ë·¹¸£±â  /  µÎµå·¯±â  /  ¾Ë·¹¸£±âºñ¿° [ÃÖ½ÅÀÚ·á]
ÇöÀçÀ§Ä¡ : ¾à¹°Á¤º¸
 
 Ãâ·Â    ¸ÞÀÏ    ¸®½ºÆ®    Ãßõ

[»çÁø¼³¸í] ÇÁ·ÎÅäÇÈ ¿¬°í 0.03%
 
ÇÁ·ÎÅäÇÈ ¿¬°í 0.03%, 0.1%

ÀÔ·ÂÀÏ:2007-07-19 / Á¶È¸¼ö:7929 / Ãßõ¼ö:140 / ÀÛ¼ºÀÚ:ÇѸ¸¿ë


»óǰ¸í : ÇÁ·ÎÅäÇȢ翬°í 0.03%, 0.1% (Protopic¢çOintment 0.03%, 0.1%)

ÀǾàǰ ±¸ºÐ : Àü¹®ÀǾàǰ

¼ººÐ : Tacrolimus

È¿´ÉÈ¿°ú : ¾ÆÅäÇǼº ÇǺο°

º¸ÇèÄÚµå :

ÇÁ·ÎÅäÇÈ¿¬°í0.03% : E21180101
ÇÁ·ÎÅäÇÈ¿¬°í0.1% : E21180111

º¸Çè¾à°¡ :

0.03%: 1,178¿ø/g(¿ë·® 10g),
0.1%: 1,534¿ø/g(¿ë·® 10g)

ƯÀåÁ¡ :

¼¼°è ÃÖÃÊÀÇ ±¹¼Ò ¸é¿ª Á¶Àý ±âÀü (Topical Immunomodulator, TIM)ÀÇ ¾ÆÅäÇǼº ÇǺο° ÇǺÎÀ§Ãà, °ú³»¼º, ÁÖ¸§, º´¼Ò¾ÇÈ­, ºÎ½Å¾ïÁ¦, ¸é¿ª¾ïÁ¦, ´ë»çÀÌ»ó µîÀÇ ½ºÅ×·ÎÀÌµå ±¹¼ÒÀû, Àü½ÅÀû ºÎÀÛ¿ëÀÌ ³ªÅ¸³ªÁö ¾Ê¾Æ ¾ÆÅäÇÇÇǺο°ÀÇ Àå±â Á¶ÀýÀÌ °¡´ÉÇÏ´Ù.

¾àÈ¿/¾à¸®


1. ÇÁ·ÎÅäÇÈÀº ¾ÆÅäÇǼº ÇǺο°ÀÇ ¹ßÁõ±âÀü¿¡ °ü¿©ÇÏ´Â T¼¼Æ÷, ºñ¸¸¼¼Æ÷ ¹× È£»ê±¸ µîÀÇ
ÀÛ¿ëÀ» ¾ïÁ¦ÇÏ¿© ÇǺο°ÁõÀ» Á¦¾îÇÔÀ¸·Î½á ¾ÆÅäÇǼº ÇǺο°¿¡ È¿´É, È¿°ú¸¦ °¡Áü

2. T¼¼Æ÷¿¡¼­ »ê»ýµÇ´Â »çÀÌÅäÄ«ÀÎ »ê»ý ¾ïÁ¦

3. ºñ¸¸¼¼Æ÷¿¡¼­ÀÇ È÷½ºÅ¸¹Î À¯¸® ¹× »çÀÌÅäÄ«ÀÎ »ê»ý ¾ïÁ¦

4. È£»ê±¸ÀÇ Ä§À±, Ȱ¼ºÈ­ ¾ïÁ¦

5. ¶û°Ô¸£Çѽº¼¼Æ÷ÀÇ Ç׿ø Á¦½Ã´É ¾ïÁ¦

¿ø·áÀǾàǰÀÇ ºÐ·®

ÇÁ·ÎÅäÇÈ ¿¬°í 0.03% : 1g Áß Tacrolimus ¼öÈ­¹° 0.306mg(Tacrolimus·Î¼­ 0.03mg)

ÇÁ·ÎÅäÇÈ ¿¬°í 0.1% : 1g Áß Tacrolimus ¼öÈ­¹° 1.02mg(Tacrolimus·Î¼­ 1.0mg)

¼º»ó

¹é»ö ³»Áö ¹ÌȲ»öÀÇ ¿¬°í

¿ë¹ý/¿ë·®

ÇÁ·ÎÅäÇÈ¿¬°í0.03%- ¼ºÀÎ ¹× 2¼¼ ÀÌ»óÀÇ ¼Ò¾Æ 1ÀÏ 2ȸ ȯºÎ¿¡ µµÆ÷
(ÇÇÁø ¼Ò½Ç ÈÄ 1ÁÖ°£ °è¼ÓÇØ¼­ Ä¡·á) ¹ÐºÀ¿ä¹ýÀº ÇÇÇÔ

ÇÁ·ÎÅäÇÈ¿¬°í0.1%- ¼ºÀÎ 1ÀÏ 2ȸ ȯºÎ¿¡ µµÆ÷
(ÇÇÁø ¼Ò½Ç ÈÄ 1ÁÖ°£ °è¼ÓÇØ¼­ Ä¡·á) ¹ÐºÀ¿ä¹ýÀº ÇÇÇÔ

¿ë·® 10g

»ç¿ë»ó ÁÖÀÇ»çÇ×

1. ºÎÀÛ¿ë: ÇǺÎÀڱذ¨, °¡·Á¿ò, °¨±â¾çÁõ»ó, ¾Ë·¯Áö¹ÝÀÀ, ÇǺÎÈ«¹Ý, µÎÅë, ÇǺΰ¨¿°Áõ,

¹ß¿­ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ½.

2. ÁÖÀÇ»çÇ×: ´ÙÀ½È¯ÀÚ¿¡´Â Åõ¿©ÇÏÁö ¸» °Í

¨ç ¹Ì¶õ ±Ë¾ç¸éÀÌ Àִ ȯÀÚ

¨è °íµµÀÇ ½ÅÀåÇØ, °íµµÀÇ °íÄ®·ý Ç÷ÁõÀÌ Àִ ȯÀÚ
(½ÅÀåÇØ, °íÄ®·ýÇ÷ÁõÀÌ ¾ÇÈ­µÉ °¡´É¼ºÀÌ ÀÖÀ½)

¨é ÀӺΠ¶Ç´Â ÀÓ½ÅÇÒ °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ

¨ê Ÿũ·Î¸®¹«½º³ª ÷°¡¹°¿¡ ´ëÇÏ¿© °ú¹ÎÁõÀÌ ±â¿Õ·ÂÀÌ Àִ ȯÀÚ

¨ë PUNA¿ä¹ý µîÀÇ Àڿܼ± ¿ä¹ýÀ» ½Ç½ÃÁßÀΠȯÀÚ

¨ì ¾î¸°¼±¾ç È«ÇÇÁõ Áúȯ(Netherton¡¯s Syndrome)ȯÀÚ

Ãë±Þ»ó ÁÖÀÇ»çÇ×

¨ç ½Ç¿Â(15¡É-30¡É)¿¡ º¸°üÇÒ °Í.

¨è Ãä°Å³ª ´õ¿î ³¯¾¾¿¡ Â÷¾È¿¡ ÀÌ ¾àÀ» µÎÁö¸» °Í.

¨é Æ©ºêÀÇ ¶Ñ²±ÀÌ Àß ´ÝÇôÀÖ´ÂÁö È®ÀÎÇÒ °Í.

¨ê ¾ÆÀ̵éÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÒ °Í.

Á¦Á¶¿ø

Astellas Pharma Manufacturing Inc.(U.S.A)

ÆÇ¸Å¿ø

Á¾ÇÕº´¿ø: Çѱ¹¾Æ½ºÅÚ¶ó½ºÁ¦¾à¢ß
Clinic: µ¿¾ÆÁ¦¾à¢ß
 
100ÀÚÆò ¾²±â  À̸§: ÀÔ·ÂÀÏ:2025-05-20 
 
ÀÛ¼ºÀÚ : Kayli
Basically, no-fault insurance is designed so that the victims of an automobile accident receive compensation from their own insurance QuotesChimp for damages that result from the collision. It is called no-fault because the respective insurance companies are responsible for the damages to their own clients without regard to whose driving errors caused the accident.
ÀÛ¼ºÀÚ : Godson
I feel safteiisd after reading that one.
ÀÛ¼ºÀÚ : Leenu
That's a smart way of lokiong at the world.
ÀÛ¼ºÀÚ : Tessie
No colmpaints on this end, simply a good piece.
 
 
°íÁ¤°Ë»ö :  ¾Ë·¹¸£±â°³·Ð  /  ¾Ë·¹¸£°Õ  /  ±â°üÁöõ½Ä  /  ¾ÆÅäÇÇÇǺο°  /  À½½Ä¾Ë·¹¸£±â  /  µÎµå·¯±â  /  ¾Ë·¹¸£±âºñ¿°  
Á¤º¸Á¦°ø¿øÄ¢¤ÓÁ¤º¸°øÀ¯¹æ¿î¿µ¿øÄ¢¤ÓÀúÀ۱ǰü·Ã¤Ó°³ÀÎÁ¤º¸º¸È£¿øÄ¢¤ÓÀ̸ÞÀϹ«´Ü¼öÁý°ÅºÎ¤Ó°íÁ¤ÇÊÁø±¸ÇÔ¤ÓºñÁ¯°ú »ç¸í
¸ðµç ±ÛÀº ÀúÀÛ±Ç ¹ýÀÇ º¸È£¸¦ ¹Þ´Â ¹Ù ¹«´Ü ÀüÀç. º¹»ç. ¹èÆ÷µîÀ» ±ÝÇÕ´Ï´Ù.